Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials.

AIMS In view of the currently available evidence from randomized trials, we aimed to compare the collective safety and efficacy of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) across the spectrum of risk and in important subgroups. METHODS AND RESULTS Trials comparing TAVI vs. SAVR were identified through Medline, Embase, and Cochrane databases. The primary outcome was death from any cause at 2 years. We performed random-effects meta-analyses to combine the available evidence and to evaluate the effect in different subgroups. This systematic review and meta-analysis is registered with PROSPERO (CRD42016037273). We identified four eligible trials including 3806 participants, who were randomly assigned to undergo TAVI (n = 1898) or SAVR (n = 1908). For the primary outcome of death from any cause, TAVI when compared with SAVR was associated with a significant 13% relative risk reduction [hazard ratio (95% CI): 0.87 (0.76-0.99); P = 0.038] with homogeneity across all trials irrespective of TAVI device (Pinteraction = 0.306) and baseline risk (Pinteraction = 0.610). In subgroup analyses, TAVI showed a robust survival benefit over SAVR for patients undergoing transfemoral access [0.80 (0.69-0.93); P = 0.004], but not transthoracic access [1.17 (0.88-1.56); P = 0.293] (Pinteraction = 0.024) and in female [0.68 (0.50-0.91); P = 0.010], but not male patients [0.99 (0.77-1.28); P = 0.952] (Pinteraction = 0.050). Secondary outcomes of kidney injury, new-onset atrial fibrillation, and major bleeding favoured TAVI, while major vascular complications, incidence of permanent pacemaker implantation, and paravalvular regurgitation favoured SAVR. CONCLUSION Compared with SAVR, TAVI is associated with a significant survival benefit throughout 2 years of follow-up. Importantly, this superiority is observed irrespective of the TAVI device across the spectrum of intermediate and high-risk patients, and is particularly pronounced among patients undergoing transfemoral TAVI and in females.

[1]  J. Coselli,et al.  3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.

[2]  J. Leipsic,et al.  Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis , 2016, The Lancet.

[3]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[4]  M. Mack,et al.  Sex-Specific Differences at Presentation and Outcomes Among Patients Undergoing Transcatheter Aortic Valve Replacement , 2016, Annals of Internal Medicine.

[5]  S. Redwood,et al.  Transcatheter Aortic Valve Replacement Using the Repositionable LOTUS Valve: United Kingdom Experience. , 2016, JACC. Cardiovascular interventions.

[6]  M. Mack,et al.  A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. , 2015, JACC. Cardiovascular interventions.

[7]  L. Räber,et al.  Procedural Results and Clinical Outcomes of Transcatheter Aortic Valve Implantation in Switzerland: An Observational Cohort Study of Sapien 3 Versus Sapien XT Transcatheter Heart Valves , 2015, Circulation. Cardiovascular interventions.

[8]  S. Windecker,et al.  Transcatheter Aortic Valve Replacement: Lessons Gained From Extreme-Risk Patients. , 2015, Journal of the American College of Cardiology.

[9]  I. Meredith,et al.  Treatment of Symptomatic Severe Aortic Stenosis With a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. , 2015, JACC. Cardiovascular interventions.

[10]  Hongyan Qiao,et al.  2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. , 2015, Journal of the American College of Cardiology.

[11]  M. Mack,et al.  5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.

[12]  P. Stella,et al.  Transcatheter Aortic Valve Implantation With the New Balloon-Expandable Sapien 3 Versus Sapien XT Valve System: A Propensity Score–Matched Single-Center Comparison , 2015, Circulation. Cardiovascular interventions.

[13]  L. W. Andersen,et al.  Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.

[14]  R. Lange,et al.  Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry. , 2015, Journal of the American College of Cardiology.

[15]  W. Banya,et al.  Long-term outcomes after transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis: the U.K. Transcatheter Aortic Valve Implantation Registry. , 2015, JACC. Cardiovascular interventions.

[16]  John D. Carroll,et al.  Clinical outcomes at 1 year following transcatheter aortic valve replacement. , 2015, JAMA.

[17]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2015, BMJ : British Medical Journal.

[18]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[19]  M. Mack,et al.  Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. , 2015, JACC. Cardiovascular interventions.

[20]  Hemang B Panchal,et al.  A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events in patients undergoing transfemoral versus transapical transcatheter aortic valve implantation using edwards valve for severe aortic stenosis. , 2014, The American journal of cardiology.

[21]  Peter Jüni,et al.  Systematic reviews and meta-analyses of randomized trials: principles and pitfalls , 2014 .

[22]  M. Mack,et al.  Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort--a analysis. , 2014, Journal of the American College of Cardiology.

[23]  Peter Jüni,et al.  Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. , 2014, Journal of the American College of Cardiology.

[24]  Maurice Buchbinder,et al.  Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.

[25]  P. Leprince,et al.  Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures: Analysis of Predictors and Impact on Long-Term Mortality Insights From the FRANCE2 Registry , 2014, Circulation.

[26]  W. O’Neill,et al.  New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. , 2013, Journal of the American College of Cardiology.

[27]  P. Serruys,et al.  Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. , 2014, The Annals of thoracic surgery.

[28]  J. Leipsic,et al.  Impact of low-profile sheaths on vascular complications during transfemoral transcatheter aortic valve replacement. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[29]  Susheel Kodali,et al.  Two-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement , 2013 .

[30]  P. Wenaweser,et al.  Atrial Fibrillation and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation , 2013, Circulation. Cardiovascular interventions.

[31]  P. Boekstegers,et al.  Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. , 2012, Journal of the American College of Cardiology.

[32]  V. Hjortdal,et al.  A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[33]  Susheel Kodali,et al.  Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. , 2012, Journal of the American College of Cardiology.

[34]  Philippe Pibarot,et al.  The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. , 2012, European heart journal.

[35]  D. Dvir,et al.  Predictors and course of high-degree atrioventricular block after transcatheter aortic valve implantation using the CoreValve Revalving System. , 2011, The American journal of cardiology.

[36]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[37]  Antonio Colombo,et al.  One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: The European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve , 2011, Circulation.

[38]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[39]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[40]  Katja Jasinskaja,et al.  Elaboration and Explanation ⋆ , 2011 .

[41]  H. Baumgartner,et al.  Gender differences in clinical presentation and surgical outcome of aortic stenosis , 2010, Heart.

[42]  Philippe Pibarot,et al.  Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement , 2009, European heart journal.

[43]  Jeroen J. Bax,et al.  The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy. , 2009, Journal of the American College of Cardiology.

[44]  P. Pibarot,et al.  Electrocardiographic changes and clinical outcomes after transapical aortic valve implantation. , 2009, American heart journal.

[45]  S. McCluskey,et al.  Acute Kidney Injury After Cardiac Surgery: Focus on Modifiable Risk Factors , 2009, Circulation.

[46]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.